Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 2Esophageal Squamous Cell Carcinoma 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Esophageal Neoplasms 1

Interventions

pembrolizumab 61Cisplatin 45Cetuximab 32Radiotherapy 25Nivolumab 22Docetaxel 16Radiotherapy, Intensity-Modulated 14Paclitaxel 13Carboplatin 13durvalumab 11Radiation 10Fluorouracil 10Magnetic Resonance Spectroscopy 9Cyclophosphamide 9fludarabine 8Erlotinib Hydrochloride 8budigalimab 7Ipilimumab 7atezolizumab 6Radiosurgery 6Gemcitabine 6Drug Therapy 6130-nm albumin-bound paclitaxel 6tremelimumab 5tislelizumab 5spartalizumab 5fludarabine phosphate 5avelumab 5Surgical Procedures, Operative 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Squamous Cell Carcinoma of Head and Neck × elgemtumab × Clear all
NCT01598077 2020-12-19

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Novartis

Phase 1 Completed
54 enrolled
BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡